Paris-based Diabnext’s mobile app tracks diabetes data so that physicians can collaborate with their patients to monitor individual patient data and provide remote care. Financial details of the acquisition were not disclosed.
Palo Alto, California-based Glooko said in a news release that the mobile app complements its product portfolio and, with Diabnext’s presence in France, can significantly increase the number of patients and healthcare providers in the territory and expand remote patient offerings under the Glooko product umbrella.
“We are very pleased to welcome the Diabnext team to Glooko and especially excited to add their well-regarded product to Glooko’s portfolio, along with their expertise in the diabetes community in France,” Glooko CEO Russ Johannesson said in the release. “The addition of Diabnext expands our offerings with a unique platform that can help us better customize the patient experience and improve health outcomes for people with diabetes. Glooko’s acquisition of Diabnext further cements our commitment to increase our global presence and continue to drive innovative solutions.”
Diabnext’s team has joined Glooko in the company’s Paris office. It will offer both platforms to the French market, with the company’s former CEO, Laurent Nicolas, set to serve as managing director as he leads the efforts in France.
“The Diabnext team is excited to be part of Glooko. We appreciate the value Glooko places on the product solutions developed for the unique needs of the French market,” Nicolas said. “Not only will this allow us to continue to serve the diabetes community, but with Glooko’s resources and capabilities in device integration, we can now offer more tools to help healthcare professionals provide better care across diabetes-related chronic conditions for the patients they serve.”
All existing patients, hospitals and clinics using Diabnext’s product will continue to be supported on the platform, the companies said. At the same time, Glooko will work to expand the adoption of the French Ministry of Health’s ETAPES program for supporting innovative digital health solutions.
Diabnext’s platform will be marketed under the name “Glooko XT.”
